Frank Litvack MD
Adult Congenital Heart Disease, Interventional Cardiology
Professor, Medicine, UCLA School of Medicine
Join to View Full Profile
8840 Wilshire Blvd2nd floorBeverly Hills, CA 90211
Phone+1 213-380-7130
Fax+1 310-967-1744
Dr. Litvack is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Cedars-Sinai Medical CenterFellowship, Cardiovascular Disease, 1982 - 1985
McGill University Faculty Medicine HospitalInternal Medicine, 1979 - 1982
McGill University Faculty of MedicineClass of 1979
Certifications & Licensure
OR State Medical License 1988 - Present
CA State Medical License 1982 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Publications & Presentations
PubMed
- 12 citationsPimecrolimus and dual pimecrolimus‐paclitaxel eluting stents decrease neointimal proliferation in a porcine modelRyan Berg, Joseph Aragon, Vladimir Royter, John F. Shanley, Greg Cogert
Catheterization and Cardiovascular Interventions. 2007-11-15 - 18 citationsOne-year clinical outcome of various doses and pharmacokinetic release formulations of paclitaxel eluted from an erodable polymer - Insight in the Paclitaxel In-Stent ...Jiro Aoki, Andrew T.L. Ong, Alexandre Abizaid, Péter Tien Heijer, Hans Bonnier
Eurointervention. 2005-08-01 - 9 citationsThe effect of variable release kinetics on Paclitaxel efficacy from a drug eluting stent in a porcine model.Joseph Aragon, Saibal Kar, Fermin O. Tio, Brett Trauthen, Alexander Parisky
Eurointervention. 2005-08-01
Press Mentions
V-wave Raises $98m to Support Further Development of Cardiac ShuntSeptember 23rd, 2020
Billionaire Efrem Kamen Pulled Cash from Otonomy Inc (OTIC) and Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Welcoming Gilead Sciences, Inc. (GILD)September 5th, 2017
V-wave Scores $28 Mln Series BJanuary 11th, 2016- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
